Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

Autor Courtin, Aurelie, Smyth, Tomoko, Hearn, Keisha, Saini, Harpreet K, Thompson, Neil T, Lyons, John F, Wallis, Nicola G
Vydáno v Br J Cancer (2016)

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to dual BRAF and MEK Inhibition in Melanoma Models

Autor Smyth, Tomoko, Paraiso, Kim H T, Hearn, Keisha, Rodriguez-Lopez, Ana M, Munck, Joanne M, Haarberg, H Eirik, Sondak, Vernon K, Thompson, Neil T, Azab, Mohammad, Lyons, John F, Smalley, Keiran S M, Wallis, Nicola G
Vydáno v Mol Cancer Ther (2014)

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors

Autor Murray, Christopher W., Berdini, Valerio, Buck, Ildiko M., Carr, Maria E., Cleasby, Anne, Coyle, Joseph E., Curry, Jayne E., Day, James E. H., Day, Phillip J., Hearn, Keisha, Iqbal, Aman, Lee, Lydia Y. W., Martins, Vanessa, Mortenson, Paul N., Munck, Joanne M., Page, Lee W., Patel, Sahil, Roomans, Susan, Smith, Kirsten, Tamanini, Emiliano, Saxty, Gordon
Vydáno v ACS Med Chem Lett (2015)